The platform uses Optina’s cerebral amyloid predictor retina scan and metabolic hyperspectral retinal camera to formulate a data-rich image from a basic eye scan. AI then analyzes the image for indication of amyloid plaques in the brain, which are linked to neurodegenerative diseases such as Alzheimer’s.
Optina’s technology offers a low-cost, non-invasive way to improve diagnosis accuracy and subsequent care management for patients with cognitive decline, a condition that can often go un- or misdiagnosed.
The FDA’s “Breakthrough Device” designation is not a safety approval but provides an expedited pathway for the review of a medical device that the agency believes has the potential to be extremely effective in diagnosing or treating life-threatening diseases.
More articles about AI:
Harvard Business Review: Look at AI as a system-wide update, not a point solution
Catasys will use AI, human interaction to address loneliness epidemic
MATTER, rMark Bio unveil matchmaking service to pair tech startups with healthcare clients
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
